Concepedia

Horst-Dieter Hummel

HH

14

Publications

1.2K

Citations

13

H-Index

2019

Active since

Affiliations

Comprehensive Cancer Center Mainfranken(Current)

Universitätsklinikum Würzburg

Amgen (United States)

Heidelberg University

University Hospital Heidelberg

Horst-Dieter Hummel is an author at Comprehensive Cancer Center Mainfranken specializing in radiation oncology, oncology, and medicine.

ORCID

Top concepts

Publications per year

2019–2024

14

Publications

14

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip et al. · New England Journal of Medicine · 2023 · 390 citations

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Luis Paz‐Ares, Stéphane Champiat, W. Victoria Lai et al. · Journal of Clinical Oncology · 2023 · 250 citations · Full text

Pasotuxizumab, a Bite <sup>®</sup> Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich et al. · Immunotherapy · 2020 · 132 citations · Full text

Evolutionary trajectories of small cell lung cancer under therapy

Julie George, Lukas Maas, Nima Abedpour et al. · Nature · 2024 · 90 citations · Full text

Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).

Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich et al. · Journal of Clinical Oncology · 2019 · 56 citations

, , +15

Rows per page

1–5 of 14